PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy

Background: A new therapeutic avenue combining Durvalumab with cisplatin-pemetrexed (Durva-CP) has delivered a promising outcome for previously untreated patients with unresectable malignant pleural mesothelioma (MPM) in clinical trials. However, the limited patient response to Durva-CP needs predic...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Andrei Gurau, Suguru Yamauchi, Kaitlyn Ecoff, Kristen P. Rodgers, James R. Eshleman, Charles Conover Talbot Jr, Peng Huang, Joshua Choi, Patrick M. Forde, Valsamo Anagnostou, Malcolm Brock, Yuping Mei
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	KeAi Communications Co., Ltd. 2025-06-01
Σειρά:	Non-coding RNA Research
Θέματα:	PD-L1 pfeRNA MPM Durvalumab Pemetrexed Cisplatin
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2468054025000253
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!